XBiotech is announcing that results from its Phase 1/2 oncology study conducted at MD Anderson Cancer Center in Houston, TX were published in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s novel, non-cytotoxic, anti-tumor therapy. The so-called true human antibody therapy was reported to have an excellent safety profile. The report describes comprehensive measures of patient performance during therapy with Xilonix. It was reported that overall, patients constitutional symptoms improved, including reduction in pain and fatigue. A highlight of the report was the finding that almost two-thirds of patients assessed with a new form of X-ray imaging demonstrated physical recovery of lean body mass (which is another way of referring to muscle mass) but moreover, that these same patients had dramatic improvement in overall survival. 

 

The importance of the article was suggested by the co-publication of a commentary piece written by world-renown researcher Dr. Charles Dinarello. In the commentary, Dinarello said, “The study is a unique contribution because it opens entire new areas in cancer therapeutics. The study also provides a rationale for early use of anti-cytokine therapy in cancer and sets the stage for use of anti-cytokine treatment in combination with kinase inhibitors and anti-immunosuppressive treatments.” 

 

Date: April 17, 2014

Source: XBiotech